Safety, Tolerability, Pharmacokinetics and Activity of K0706

Part A ( for Healthy volunteers) of the study is completed Part B (for CML subject ) of the
study is ongoing. (Recruitment for Part B initiated in April 2017) Part C of study in
subjects with CML and Ph+ ALL is on-going. (Open for Recruitment )

Inclusion Criteria:

- Willing and able to give written, and dated, informed consent

- Male or female aged ≥ 18 years

- Willing and able to comply with the scheduled visits

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Subjects diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, or Ph+ ALL

Exclusion Criteria:

- Any major surgery, as determined by the Investigator, within 4 weeks of IMP
administration

- Inability to undergo venipuncture and/or tolerate venous access

- Positive exclusion tests: urine pregnancy tests (if applicable), HIV, hepatitis B
surface antigen, or hepatitis C virus

- Known or suspected history of significant drug abuse as judged by the Investigator